Work

JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps4147

Authors: Yung-Jue Bang, Yoon-Koo Kang, Maria Alsina, Zev A. Wainberg, Ian Chau, Jin Zhu, Wai Y. Chan, Premal H. Patel, Raymond D. Meng, Jaffer A. Ajani

Institutions: Seoul National University, Seoul National University Hospital, Asan Medical Center, University of Ulsan, Vall d'Hebron Hospital Universitari, University of California, Los Angeles, Royal Marsden NHS Foundation Trust, Genentech, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603764639

Cites:

Cited by: 7

Related to: 10